MK0457 in Patients With Leukemia (0457-003)
In this study participants with relapsed/refractory leukemia will be given MK-0457 in sequential cohorts and with varying treatment duration to determine the maximum tolerated dose (MTD) for MK-0457.
Chronic Myelogenous Leukemia in Blast Crisis|Lymphocytic Leukemia, B Cell, Acute|Myelodysplastic Syndromes|Myelogenous Leukemia, Chronic
DRUG: MK0457
Number of Participants Experiencing Dose-Limiting Toxicities (DLTs), Part 1: up to 5 days, Part 2: up to 24 hours
Hematological response rate to MK-0457 as a 5-day CIV infusion, At the end of each cycle (up to 18 months)
In this study participants with relapsed/refractory leukemia will be given MK-0457 in sequential cohorts and with varying treatment duration to determine the maximum tolerated dose (MTD) for MK-0457.